Neuren Pharmaceuticals (ASX: NEU) has announced the appointment of Mr Joe Basile as an independent non-executive director.
Mr Basile has extensive experience in the pharmaceutical industry and brings deep knowledge in corporate mergers and acquisitions, capital management, and overseeing expansion activities.
Neuren Pharmaceuticals is developing two drug therapies for multiple neurological disorders that have limited or no approved treatment options.
Its drug, Trofinetide has been submitted for Priority Review by the US Food and Drug Administration, and has granted an exclusive licence to Acadia Pharmaceuticals for the development and commercialisation of trofinetide in North America.